Drug intelligence / Profile preview

ivonescimab + paclitaxel

Development stage: Phase 2
Lead developer: Akeso
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous

Overview

Ivonescimab (AK112) + paclitaxel is a combination therapy that pairs a bispecific antibody with a chemotherapy agent. Ivonescimab is a novel bispecific antibody that targets both PD-1 and VEGF pathways simultaneously, combining immune checkpoint inhibition with anti-angiogenic effects. Paclitaxel is a well-established chemotherapy drug that works by stabilizing microtubules and preventing cell division. This combination approach aims to enhance anti-tumor efficacy through complementary mechanisms of action.

Other names: Ivonescimab + paclitaxel

Targets

PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)TUBB (Tubulin (alpha and beta subunits))Microtubule

Beyond the preview

Go deeper on ivonescimab + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ivonescimab + paclitaxel.